XML 15 R6.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Cash flows from operating activities:    
Net income $ 21,346,450 $ 1,149,411
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization 4,054,109 3,973,582
Stock compensation 828,193 861,837
Bad debt expense 27,729 11,116
Gain on sale of real estate assets, net (2,294,574) (4,057,527)
Gain on deconsolidation of SPAC investment (40,321,483) 0
Net change in fair value marketable securities (169,530) 70,183
Net change in fair value SPAC Trust Account (1,209,542) (811,687)
Amortization of financing costs 263,863 180,250
Amortization of below-market leases (3,731) (41,167)
Straight-line rent adjustment (280,619) (148,181)
Changes in operating assets and liabilities:    
Other assets (92,877) 585,984
Accounts payable and accrued liabilities 378,761 245,652
Accounts payable and accrued liabilities for the SPAC 652,577 316,128
Accrued real estate taxes (373,343) (447,279)
Net cash provided by operating activities 488,137 1,888,302
Cash flows from investing activities:    
Real estate acquisitions (13,715,923) (8,087,250)
Additions to buildings and tenant improvements (2,817,786) (1,939,712)
Investment in marketable securities (2,083,328) (1,243,672)
Proceeds from sale of marketable securities 2,302,456 1,787,695
Investment of SPAC IPO proceeds into Trust Account (624,998) (134,895,000)
Withdrawals from Trust Account for SPAC taxes 832,480 0
Withdrawals from Trust Account for Redemption of SPAC Shares 137,157,011 0
Deletions / (additions) to deferred leasing costs 5,808 (53,377)
Proceeds from sales of real estate, net 7,113,065 20,603,179
Net cash provided by (used in) investing activities 128,168,785 (123,828,137)
Cash flows from financing activities:    
Proceeds from mortgage notes payable, net of issuance costs 13,400,934 14,992,425
Repayment of mortgage notes payable (7,885,953) (9,586,079)
Payment of deferred offering costs 0 (3,201,266)
Distributions to noncontrolling interests, net (3,013,831) (3,812,698)
Proceeds from initial public offering of SPAC 0 132,859,920
SPAC offering non-controlling interest adjustment 0 (609,920)
Redemption of SPAC shares (137,157,011) 0
Repurchase of Series A Common Stock, at cost 0 (277,696)
Dividends paid to Series D Preferred Stockholders (1,595,606) (1,616,398)
Dividends paid to Series A Common Stockholders (892,646) (2,857,081)
Net cash (used in) provided by financing activities (137,394,883) 125,806,821
Net (decrease) increase in cash equivalents and restricted cash (8,737,961) 3,866,986
Cash, cash equivalents and restricted cash - beginning of period 16,516,725 14,702,089
Cash, cash equivalents and restricted cash - end of period $ 7,778,764 $ 18,569,075
Non-cash financing activities:    
Potentially convertible common stock for SPAC (in shares) 0 134,895,000
Dividends payable $ 478,253  
Dividends payable 478,253  
Mortgage Notes [Member]    
Supplemental disclosure of cash flow information:    
Interest paid 3,637,980 $ 3,038,713
Series D Preferred Stock [Member]    
Cash flows from financing activities:    
Repurchase of Series D Preferred Stock, at cost (250,770) (84,386)
Non-cash financing activities:    
Dividends payable 175,758 178,916
Dividends payable 175,758 178,916
Common Class A [Member]    
Non-cash financing activities:    
Dividends payable 302,495 0
Dividends payable 302,495 0
Conduit Pharmaceuticals Inc [Member]    
Adjustments to reconcile net income to net cash provided by operating activities:    
Net change in fair value marketable securities $ 17,682,154 $ 0